Cargando…
Assessment of Noninvasive Markers of Steatosis and Liver Fibrosis in Human Immunodeficiency Virus-Monoinfected Patients on Stable Antiretroviral Regimens
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is a major nonacquired immune deficiency syndrome-defining condition for persons with human immunodeficiency virus (PWH). We aimed to validate noninvasive tests for the diagnosis of NAFLD in PWH. METHODS: This is a cross-sectional study of PWH on...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297309/ https://www.ncbi.nlm.nih.gov/pubmed/35873289 http://dx.doi.org/10.1093/ofid/ofac279 |
_version_ | 1784750449219338240 |
---|---|
author | Busca, C Sánchez-Conde, M Rico, M Rosas, M Valencia, E Moreno, A Moreno, V Martín-Carbonero, L Moreno, S Pérez-Valero, I Bernardino, J I Arribas, J R González, J Olveira, A Castillo, P Abadía, M Guerra, L Mendez, C Montes, M L |
author_facet | Busca, C Sánchez-Conde, M Rico, M Rosas, M Valencia, E Moreno, A Moreno, V Martín-Carbonero, L Moreno, S Pérez-Valero, I Bernardino, J I Arribas, J R González, J Olveira, A Castillo, P Abadía, M Guerra, L Mendez, C Montes, M L |
author_sort | Busca, C |
collection | PubMed |
description | BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is a major nonacquired immune deficiency syndrome-defining condition for persons with human immunodeficiency virus (PWH). We aimed to validate noninvasive tests for the diagnosis of NAFLD in PWH. METHODS: This is a cross-sectional study of PWH on stable antiretroviral therapy with persistently elevated transaminases and no known liver disease. The area under the receiver operating characteristic curve (AUROC) was calculated to compare the diagnostic accuracy of liver biopsy with abdominal ultrasound, transient elastography (TE) (including controlled attenuation parameter [CAP]), and noninvasive markers of steatosis (triglyceride and glucose index [TyG], hepatic steatosis index [HSI], fatty liver index [FLI]) and fibrosis ([FIB]-4, aminotransferase-to-platelet ratio index [APRI], NAFLD fibrosis score). We developed a diagnostic algorithm with serial combinations of markers. RESULTS: Of 146 patients with increased transaminase levels, 69 underwent liver biopsy (90% steatosis, 61% steatohepatitis, and 4% F ≥3). The AUROC for steatosis was as follows: ultrasound, 0.90 (0.75–1); CAP, 0.94 (0.88–1); FLI, 0.81 (0.58–1); HSI, 0.74 (0.62–0.87); and TyG, 0.75 (0.49–1). For liver fibrosis ≥F3, the AUROC for TE, APRI, FIB-4, and NAFLD fibrosis score was 0.92 (0.82–1), 0.96 (0.90–1), 0.97 (0.93–1), and 0.85 (0.68–1). Optimal diagnostic performance for liver steatosis was for 2 noninvasive combined models of tests with TyG and FLI/HSI as the first tests and ultrasound or CAP as the second tests: AUROC = 0.99 (0.97–1, P < .001) and 0.92 (0.77–1, P < .001). CONCLUSIONS: Ultrasound and CAP performed best in diagnosing liver steatosis, and FLI, TyG, and HSI performed well. We propose an easy-to-implement algorithm with TyG or FLI as the first test and ultrasound or CAP as the second test to accurately diagnose or exclude NAFLD. |
format | Online Article Text |
id | pubmed-9297309 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-92973092022-07-21 Assessment of Noninvasive Markers of Steatosis and Liver Fibrosis in Human Immunodeficiency Virus-Monoinfected Patients on Stable Antiretroviral Regimens Busca, C Sánchez-Conde, M Rico, M Rosas, M Valencia, E Moreno, A Moreno, V Martín-Carbonero, L Moreno, S Pérez-Valero, I Bernardino, J I Arribas, J R González, J Olveira, A Castillo, P Abadía, M Guerra, L Mendez, C Montes, M L Open Forum Infect Dis Major Article BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is a major nonacquired immune deficiency syndrome-defining condition for persons with human immunodeficiency virus (PWH). We aimed to validate noninvasive tests for the diagnosis of NAFLD in PWH. METHODS: This is a cross-sectional study of PWH on stable antiretroviral therapy with persistently elevated transaminases and no known liver disease. The area under the receiver operating characteristic curve (AUROC) was calculated to compare the diagnostic accuracy of liver biopsy with abdominal ultrasound, transient elastography (TE) (including controlled attenuation parameter [CAP]), and noninvasive markers of steatosis (triglyceride and glucose index [TyG], hepatic steatosis index [HSI], fatty liver index [FLI]) and fibrosis ([FIB]-4, aminotransferase-to-platelet ratio index [APRI], NAFLD fibrosis score). We developed a diagnostic algorithm with serial combinations of markers. RESULTS: Of 146 patients with increased transaminase levels, 69 underwent liver biopsy (90% steatosis, 61% steatohepatitis, and 4% F ≥3). The AUROC for steatosis was as follows: ultrasound, 0.90 (0.75–1); CAP, 0.94 (0.88–1); FLI, 0.81 (0.58–1); HSI, 0.74 (0.62–0.87); and TyG, 0.75 (0.49–1). For liver fibrosis ≥F3, the AUROC for TE, APRI, FIB-4, and NAFLD fibrosis score was 0.92 (0.82–1), 0.96 (0.90–1), 0.97 (0.93–1), and 0.85 (0.68–1). Optimal diagnostic performance for liver steatosis was for 2 noninvasive combined models of tests with TyG and FLI/HSI as the first tests and ultrasound or CAP as the second tests: AUROC = 0.99 (0.97–1, P < .001) and 0.92 (0.77–1, P < .001). CONCLUSIONS: Ultrasound and CAP performed best in diagnosing liver steatosis, and FLI, TyG, and HSI performed well. We propose an easy-to-implement algorithm with TyG or FLI as the first test and ultrasound or CAP as the second test to accurately diagnose or exclude NAFLD. Oxford University Press 2022-06-09 /pmc/articles/PMC9297309/ /pubmed/35873289 http://dx.doi.org/10.1093/ofid/ofac279 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Major Article Busca, C Sánchez-Conde, M Rico, M Rosas, M Valencia, E Moreno, A Moreno, V Martín-Carbonero, L Moreno, S Pérez-Valero, I Bernardino, J I Arribas, J R González, J Olveira, A Castillo, P Abadía, M Guerra, L Mendez, C Montes, M L Assessment of Noninvasive Markers of Steatosis and Liver Fibrosis in Human Immunodeficiency Virus-Monoinfected Patients on Stable Antiretroviral Regimens |
title | Assessment of Noninvasive Markers of Steatosis and Liver Fibrosis in Human Immunodeficiency Virus-Monoinfected Patients on Stable Antiretroviral Regimens |
title_full | Assessment of Noninvasive Markers of Steatosis and Liver Fibrosis in Human Immunodeficiency Virus-Monoinfected Patients on Stable Antiretroviral Regimens |
title_fullStr | Assessment of Noninvasive Markers of Steatosis and Liver Fibrosis in Human Immunodeficiency Virus-Monoinfected Patients on Stable Antiretroviral Regimens |
title_full_unstemmed | Assessment of Noninvasive Markers of Steatosis and Liver Fibrosis in Human Immunodeficiency Virus-Monoinfected Patients on Stable Antiretroviral Regimens |
title_short | Assessment of Noninvasive Markers of Steatosis and Liver Fibrosis in Human Immunodeficiency Virus-Monoinfected Patients on Stable Antiretroviral Regimens |
title_sort | assessment of noninvasive markers of steatosis and liver fibrosis in human immunodeficiency virus-monoinfected patients on stable antiretroviral regimens |
topic | Major Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297309/ https://www.ncbi.nlm.nih.gov/pubmed/35873289 http://dx.doi.org/10.1093/ofid/ofac279 |
work_keys_str_mv | AT buscac assessmentofnoninvasivemarkersofsteatosisandliverfibrosisinhumanimmunodeficiencyvirusmonoinfectedpatientsonstableantiretroviralregimens AT sanchezcondem assessmentofnoninvasivemarkersofsteatosisandliverfibrosisinhumanimmunodeficiencyvirusmonoinfectedpatientsonstableantiretroviralregimens AT ricom assessmentofnoninvasivemarkersofsteatosisandliverfibrosisinhumanimmunodeficiencyvirusmonoinfectedpatientsonstableantiretroviralregimens AT rosasm assessmentofnoninvasivemarkersofsteatosisandliverfibrosisinhumanimmunodeficiencyvirusmonoinfectedpatientsonstableantiretroviralregimens AT valenciae assessmentofnoninvasivemarkersofsteatosisandliverfibrosisinhumanimmunodeficiencyvirusmonoinfectedpatientsonstableantiretroviralregimens AT morenoa assessmentofnoninvasivemarkersofsteatosisandliverfibrosisinhumanimmunodeficiencyvirusmonoinfectedpatientsonstableantiretroviralregimens AT morenov assessmentofnoninvasivemarkersofsteatosisandliverfibrosisinhumanimmunodeficiencyvirusmonoinfectedpatientsonstableantiretroviralregimens AT martincarbonerol assessmentofnoninvasivemarkersofsteatosisandliverfibrosisinhumanimmunodeficiencyvirusmonoinfectedpatientsonstableantiretroviralregimens AT morenos assessmentofnoninvasivemarkersofsteatosisandliverfibrosisinhumanimmunodeficiencyvirusmonoinfectedpatientsonstableantiretroviralregimens AT perezvaleroi assessmentofnoninvasivemarkersofsteatosisandliverfibrosisinhumanimmunodeficiencyvirusmonoinfectedpatientsonstableantiretroviralregimens AT bernardinoji assessmentofnoninvasivemarkersofsteatosisandliverfibrosisinhumanimmunodeficiencyvirusmonoinfectedpatientsonstableantiretroviralregimens AT arribasjr assessmentofnoninvasivemarkersofsteatosisandliverfibrosisinhumanimmunodeficiencyvirusmonoinfectedpatientsonstableantiretroviralregimens AT gonzalezj assessmentofnoninvasivemarkersofsteatosisandliverfibrosisinhumanimmunodeficiencyvirusmonoinfectedpatientsonstableantiretroviralregimens AT olveiraa assessmentofnoninvasivemarkersofsteatosisandliverfibrosisinhumanimmunodeficiencyvirusmonoinfectedpatientsonstableantiretroviralregimens AT castillop assessmentofnoninvasivemarkersofsteatosisandliverfibrosisinhumanimmunodeficiencyvirusmonoinfectedpatientsonstableantiretroviralregimens AT abadiam assessmentofnoninvasivemarkersofsteatosisandliverfibrosisinhumanimmunodeficiencyvirusmonoinfectedpatientsonstableantiretroviralregimens AT guerral assessmentofnoninvasivemarkersofsteatosisandliverfibrosisinhumanimmunodeficiencyvirusmonoinfectedpatientsonstableantiretroviralregimens AT mendezc assessmentofnoninvasivemarkersofsteatosisandliverfibrosisinhumanimmunodeficiencyvirusmonoinfectedpatientsonstableantiretroviralregimens AT montesml assessmentofnoninvasivemarkersofsteatosisandliverfibrosisinhumanimmunodeficiencyvirusmonoinfectedpatientsonstableantiretroviralregimens |